US biomedical company receives approval to treat wounds with Australian sheep blowfly larvae

American biomedical company Cuprina Holdings has received regulatory approval to use Australian sheep blowfly (Lucilia cuprina) larvae for wound care. The larvae feed on dead tissue, helping to clean difficult-to-treat wounds and promote healing. While larval therapy is not a new medical method, this approval marks an important step in the official recognition of biotherapy.

American biomedical company Cuprina Holdings has received regulatory approval to use Australian sheep blowfly, or Lucilia cuprina, larvae for wound care. The larvae feed on dead tissue, cleaning wounds and promoting healing-a scientifically proven method that still strikes many people as unsettling.

An old method, new recognition

Larval therapy, or the use of insect larvae to treat wounds, has been employed in medicine for centuries. It was particularly well documented during World War I and World War II, when physicians observed that larvae that had infected wounds actually aided recovery. Today, this method is used primarily in treating diabetic ulcers and chronic wounds where conventional medications have failed to produce desired results.

How it works

Lucilia cuprina larvae feed exclusively on necrotic, or dead, tissue, leaving living tissue untouched. At the same time, they secrete enzymes and antimicrobial substances that help cleanse the wound and prevent infection from spreading. Cuprina Holdings' approach brings this biological therapy into a modern regulated medical system, ensuring the safety and quality control of the larvae.

The company's approval opens the door for broader clinical use of the treatment method in the United States, where chronic wounds are a significant public health problem, particularly among elderly patients and those with diabetes.